Clinical trial
A Phase 1, Multicenter Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of GCC2005 With Lymphodepleting Chemotherapy in Treatment of Patients With Relapsed or Refractory NK and T-cell Malignancies
NCT06699771 is registered in ClinicalTrials.gov with GC Cell Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Multicenter Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of GCC2005 With Lymphodepleting Chemotherapy in Treatment of Patients With Relapsed or Refractory NK and T-cell Malignancies
- Lead sponsor
- GC Cell Corporation
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- March 7, 2025
- Completion date
- August 31, 2027
- Enrollment
- 53 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.